SLC45A3 and prostate carcinoma: A prior study by Wu et al.34 reported a case of prostate cancer with the SLC45A3 non-coding exon 1 fused to the intact coding region of FGFR2, in which the SLC45A3-FGFR2 fusion was predicted to drive the overexpression of wildtype FGFR2. Thus, the SLC20A2-FGFR1 fusion observed in the current study may also have been able to drive the overexpression of wildtype FGFR1, although additional studies are needed to test this possibility.